keynote-189: clinical implications in patients with less than 1% tumor pd-l1 expression (bmic-033)
Published 6 years ago • 318 plays • Length 6:32Download video MP4
Download video MP3
Similar videos
-
6:16
keynote-189: clinical implications in patients with low (1-49%) tumor pd-l1 expression (bmic-032)
-
7:58
keynote-189: clinical implications for high tumor pd-l1 expression (bmic-031)
-
4:53
chemo-immunotherapy in nsclc: the keynote-189 trial
-
4:21
optimizing use of the keynote-189 regimen in mnsclc
-
2:25
dr. gadgeel on updated keynote-189 data in nsclc
-
10:32
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
8:13
has the keynote-189 trial defined a clear standard of care? (bmic-022)
-
5:42
keynote-189: chemotherapy and pembrolizumab in mnsclc
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
5:43
advanced-stage nsclc: keynote-189’s role in treatment
-
1:08
dr. stinchcombe on the keynote-189 trial in lung cancer
-
3:23
sequencing therapy in nsclc
-
5:33
significance of keynote-189 in nsclc
-
10:34
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
2:11
edward b. garon, md, on the implications of keynote-189
-
1:55
dr. kim on the keynote-189 trial in metastatic nsclc
-
5:12
nondriver mnsclc: stratifying to the keynote-189 regimen
-
2:02
keynote-189: chemo plus pembrolizumab for nsclc
-
5:00
administering the keynote-189 regimen in nondriver mnsclc